ES2186821T3 - Derivados de 6- bencil- 2h-piridazin-3-ona, su preparacion y s u uso como inhibidores de la prostaglandin-g/h sintasa i y ii (cox i y cox ii). - Google Patents

Derivados de 6- bencil- 2h-piridazin-3-ona, su preparacion y s u uso como inhibidores de la prostaglandin-g/h sintasa i y ii (cox i y cox ii).

Info

Publication number
ES2186821T3
ES2186821T3 ES97108260T ES97108260T ES2186821T3 ES 2186821 T3 ES2186821 T3 ES 2186821T3 ES 97108260 T ES97108260 T ES 97108260T ES 97108260 T ES97108260 T ES 97108260T ES 2186821 T3 ES2186821 T3 ES 2186821T3
Authority
ES
Spain
Prior art keywords
sub
rent
cox
halo
prostaglandin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97108260T
Other languages
English (en)
Inventor
Darin Arthur Allen
James Patrick Dunn
Eric Brian Sjogren
David Bernard Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2186821T3 publication Critical patent/ES2186821T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPUESTOS DE FORMULA I: EN DONDE LA LINEA PUNTEADA INDICA UN ENLACE OPCIONAL; R{SUB,1} ES H, HALO, ALQUILO, ALQUILOXI, AMINO, ALQUILAMINO, DIALQUILAMINO O ACILAMINO; R{SUB,3} Y R{SUB,4} SON INDEPENDIENTEMENTE H, HALO, ALQUILO, ALQUILOXI O HIDROXI; R{SUB,5} ES H, HALO, ALQUILO, ALQUILTIO, ALQUILOXI, ALQUENILOXI, ALQUINILO O ALQUENILO; CON LA CONDICION DE QUE AL MENOS UNO DE R{SUB,1}, R{SUB,3}, R{SUB,4} Y R{SUB,5} ES H; R{SUB,7} ES H, ALQUILO, CIANO O AMIDO; R{SUB,10} ES UN GRUPO REPRESENTADO POR LA FORMULA (A), (B) O (C): DONDE: X ES O O S; R{SUB,12}, R{SUB,13}, R{SUB,15} Y R{SUB,16} SON INDEPENDIENTEMENTE H, HALO, ALQUILO, ALQUILOXI O ALQUILTIO; Y R{SUB,14} ES H, HALO, ALQUILO, ALQUILTIO, ALQUILOXI, ALQUENILOXI, ALQUINILO, ALQUENILO O ,2}NR{SUB,18}R{SUB,19}, DONDE R{SUB,18} Y R{SUB,19} SON INDEPENDIENTEMENTE H O ALQUILO; SIEMPRE Y CUANDO AL MENOS DOS DE R{SUB,12}, R{SUB,13}, R{SUB,14}, R{SUB,15} Y R{SUB,16} SON H, Y QUE SI SOLO DOS DE R{SUB,12}, R{SUB,13}, R{SUB,15} Y R{SUB,16} SON H, LOSSUSTITUYENTES QUE NO SON HIDROGENO NO ESTAN TODOS ADYACENTES; Y AL MENOS UNO DE R{SUB,12} Y R{SUB,16} ES H CUANDO NI R{SUB,1} NI R{SUB,3} SON H; Y R{SUB,20} ES H, ALQUILO, HALOALQUILO, HIDROXIALQUILO O ALQUENILO. LA INVENCION SE REFIERE ASIMISMO A SUS SALES FARMACEUTICAMENTE ACEPTABLES QUE TAMBIEN SON INHIBIDORES DE LA PROSTAGLANDIN IINFLAMATORIOS Y ANALGESICOS.
ES97108260T 1996-05-30 1997-05-22 Derivados de 6- bencil- 2h-piridazin-3-ona, su preparacion y s u uso como inhibidores de la prostaglandin-g/h sintasa i y ii (cox i y cox ii). Expired - Lifetime ES2186821T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1867296P 1996-05-30 1996-05-30

Publications (1)

Publication Number Publication Date
ES2186821T3 true ES2186821T3 (es) 2003-05-16

Family

ID=21789188

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97108260T Expired - Lifetime ES2186821T3 (es) 1996-05-30 1997-05-22 Derivados de 6- bencil- 2h-piridazin-3-ona, su preparacion y s u uso como inhibidores de la prostaglandin-g/h sintasa i y ii (cox i y cox ii).

Country Status (13)

Country Link
US (1) US5886178A (es)
EP (1) EP0810218B1 (es)
JP (1) JP2790450B2 (es)
CN (1) CN1136197C (es)
AR (1) AR008377A1 (es)
AT (1) ATE229007T1 (es)
BR (1) BR9703332A (es)
CA (1) CA2205757C (es)
DE (1) DE69717537T2 (es)
DK (1) DK0810218T3 (es)
ES (1) ES2186821T3 (es)
PT (1) PT810218E (es)
TR (1) TR199700419A2 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1037927T3 (da) 1997-12-08 2004-09-06 Emd Lexigen Res Ct Corp Heterodimere fusionsproteiner, der er nyttige til målrettet immunterapi og generel immunstimulering
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
BR9909583A (pt) * 1998-04-15 2002-01-15 Lexigen Pharm Corp Aumento da resposta imune mediado por uma proteìna de fusão anticorpo-citocina por co-administração com inibidor de angiogênese
CA2374260A1 (en) 1999-06-01 2000-12-07 The University Of Texas Southwestern Medical Center Method of treating hair loss using sulfonyl thyromimetic compounds
US6680344B1 (en) 1999-06-01 2004-01-20 The University Of Texas Southwestern Medical Center Method of treating hair loss using diphenylmethane derivatives
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
CA2380331C (en) 1999-08-09 2012-11-20 Lexigen Pharmaceuticals Corp. Multiple cytokine-antibody complexes
JP2003514552A (ja) 1999-11-12 2003-04-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 改善された性質を有するエリトロポエチンの形態
JP5179689B2 (ja) * 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
CN1270775C (zh) * 2000-06-29 2006-08-23 默克专利有限公司 通过与免疫细胞因子摄入促进剂联合治疗来增强抗体－细胞因子融合蛋白介导的免疫反应
US7151102B2 (en) * 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
DK1366067T3 (da) * 2001-03-07 2012-10-22 Merck Patent Gmbh Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
CA2446087C (en) * 2001-05-03 2013-06-18 Stephen D. Gillies Recombinant tumor specific antibody and use thereof
EP1454138B1 (en) 2001-12-04 2012-01-18 Merck Patent GmbH Immunocytokines with modulated selectivity
DE60335359D1 (de) * 2002-04-30 2011-01-27 Kudos Pharm Ltd Phthalazinonderivate
ATE471946T1 (de) * 2002-12-17 2010-07-15 Merck Patent Gmbh Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
US7449464B2 (en) * 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
CN100469769C (zh) * 2003-03-24 2009-03-18 弗·哈夫曼-拉罗切有限公司 作为逆转录酶抑制剂的苄基-哒嗪酮
CA2559552A1 (en) * 2004-03-23 2005-09-29 F. Hoffmann-La Roche Ag Benzyl-pyridazinone derivatives as non-nucleoside reverse transcriptase inhibitors
WO2005100323A1 (en) * 2004-04-15 2005-10-27 F. Hoffmann-La Roche Ag Process for preparing pyridazinone compounds
KR20070057859A (ko) * 2004-08-26 2007-06-07 쿠도스 파마슈티칼스 리미티드 4-헤테로아릴메틸 치환된 프탈라지논 유도체
GB0419072D0 (en) * 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
GB0428111D0 (en) * 2004-12-22 2005-01-26 Kudos Pharm Ltd Pthalazinone derivatives
JP2009510013A (ja) * 2005-09-30 2009-03-12 エフ．ホフマン−ラ ロシュ アーゲー Ｎｎｒｔ阻害剤
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
GB0610680D0 (en) * 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
WO2007144652A2 (en) * 2006-06-15 2007-12-21 Kudos Pharmaceuticals Limited Parp inhibitors
JP2009539962A (ja) * 2006-06-15 2009-11-19 クドス ファーマシューティカルズ リミテッド Ｐａｒｐ阻害剤としての２−オキシヘテロアリールアミド誘導体
EP2041087A1 (en) * 2006-06-15 2009-04-01 Kudos Pharmaceuticals Limited 2 -oxybenzamide derivatives as parp inhibitors
US20080280910A1 (en) * 2007-03-22 2008-11-13 Keith Allan Menear Phthalazinone derivatives
TW200900396A (en) * 2007-04-10 2009-01-01 Kudos Pharm Ltd Phthalazinone derivatives
US20090023727A1 (en) * 2007-07-05 2009-01-22 Muhammad Hashim Javaid Phthalazinone derivatives
CN101809017A (zh) 2007-09-14 2010-08-18 阿斯利康(瑞典)有限公司 酞嗪酮衍生物
KR101598231B1 (ko) * 2007-10-17 2016-02-26 쿠도스 파마슈티칼스 리미티드 4-[3-(4-시클로프로판카르보닐-피페라진-1-카르보닐)-4-플루오로-벤질]-2ｈ-프탈라진-1-온
CN101855221B (zh) 2007-11-15 2013-10-30 P.安杰莱蒂分子生物学研究所 作为parp抑制剂的哒嗪酮衍生物
AR070221A1 (es) 2008-01-23 2010-03-25 Astrazeneca Ab Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
EP2346495B2 (en) * 2008-10-07 2023-05-24 Kudos Pharmaceuticals Limited Pharmaceutical formulation 514
AR079774A1 (es) * 2009-07-15 2012-02-22 Astrazeneca Ab Compuesto de ftalazinona como forma cristalina c , composicion farmaceutica y usos del mismo
GB201219820D0 (en) 2012-11-05 2012-12-19 Isis Innovation Compounds
ES2544869B2 (es) * 2014-03-04 2016-01-18 Universidade De Vigo Derivados de piridazin-3(2H)-ona inhibidores selectivos de la isoforma B de la monoaminooxidasa
CN106146404B (zh) * 2015-04-15 2020-03-20 江苏恩华药业股份有限公司 哒嗪酮类衍生物及其应用
WO2017150654A1 (en) * 2016-03-04 2017-09-08 Otsuka Pharmaceutical Co., Ltd. 5-methyl-6-phenyl-4,5-dihydro-2h-pyridazin-3-one derivative

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3752826A (en) * 1970-01-26 1973-08-14 Mcneilab Inc Aroyl substituted pyrroles
US4599332A (en) * 1983-12-07 1986-07-08 Warner-Lambert Company 4,5-dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]-ethenyl]-3(2H)-pyridazinones and related compounds
IE913866A1 (en) * 1990-11-28 1992-06-03 Ici Plc Aryl derivatives
US5622948A (en) * 1994-12-01 1997-04-22 Syntex (U.S.A.) Inc. Pyrrole pyridazine and pyridazinone anti-inflammatory agents

Also Published As

Publication number Publication date
ATE229007T1 (de) 2002-12-15
EP0810218A1 (en) 1997-12-03
DE69717537T2 (de) 2003-11-06
BR9703332A (pt) 1998-09-22
DK0810218T3 (da) 2003-03-24
DE69717537D1 (de) 2003-01-16
TR199700419A2 (xx) 1997-12-21
AR008377A1 (es) 2000-01-19
CA2205757A1 (en) 1997-11-30
EP0810218B1 (en) 2002-12-04
JP2790450B2 (ja) 1998-08-27
CA2205757C (en) 2006-01-24
JPH1045723A (ja) 1998-02-17
US5886178A (en) 1999-03-23
CN1169426A (zh) 1998-01-07
CN1136197C (zh) 2004-01-28
PT810218E (pt) 2003-03-31

Similar Documents

Publication Publication Date Title
ES2186821T3 (es) Derivados de 6- bencil- 2h-piridazin-3-ona, su preparacion y s u uso como inhibidores de la prostaglandin-g/h sintasa i y ii (cox i y cox ii).
DZ3482A1 (fr) Secretagogues de l'hormone de croissance
ES2036551T3 (es) Compuestos heterociclicos.
ES2064700T3 (es) Derivados de adenosina con actividad farmaceutica como antihipertensivos.
TR200102800T2 (tr) Yeni bileşikler.
HN1999000149A (es) Derivados de 4,4-biarilpiperidina
ES2194314T3 (es) Derivados de benzopirano sustituidos para el tratamiento de inflamaciones.
ES2159738T3 (es) Derivados de benzamida y su uso como antagonistas de vasopresina.
GT200100137A (es) Pro-drogas de derivados de 4-fenil-piridina.
TR200101398T2 (tr) Pirolidin türevleri-CCR-3 reseptörü antagonistleri.
TR199801594A2 (xx) CCR-3 resept�r antagonistleri.
DK0889876T3 (da) Meta-substituerede phenylensulfonamidderivater
SE9500342D0 (sv) Novel chain terminators, the use thereof for nucleic acid sequencing and synthesis and a method of their preparation
NO20020725D0 (no) Celleadhesjonsinhibitorer
BR0110998A (pt) Derivados de fenilglicina
SE9604341D0 (sv) Hepta-peptide oxytocin analogue
BR0113162A (pt) Ariloxialquilaminas nao-imidazóis
ES2162299T3 (es) Mezclas, que contienen monomeros y estabilizantes.
ES2183340T3 (es) Procedimiento para la preparcion de compuestos de 4-bromometil-bifenilo.
TW427982B (en) Polysubstituted 3-acylamino-5-phenyl-1,4-benzodiazepin-2-one derivatives, process for their preparation and the pharmaceutical compositions containing them
IL136911A0 (en) Heterocyclic topoisomerase poisons
ES2043863T3 (es) Procedimiento para preparar derivados de la 1,2,5,6-tetrahidropiridina.
ES2169886T3 (es) Derivados condensados de la piperidina como inhibidor de sintesis de monoxido de nitrogeno.
ES2053511T3 (es) Derivados de acidos aminocarboxilicos biciclicos, procedimiento y productos intermedios para su preparacion, asi como su empleo.
BR9916807A (pt) Antagonistas de 5ht1 para terapia antidepressiva